Jordi Rodon

Jordi Rodon

Auto-generated profile, based on publicly available information

Jordi Rodon

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2013 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
JRJordi Rodon
Jordi Rodon
RDRodrigo Dienstmann
Rodrigo Dienstmann
VSVioleta Serra
Violeta Serra
Josep TaberneroJosep Tabernero
Josep Tabernero

8 August 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
LELars D. Engstrom
Lars D. Engstrom
RARuth Aranda
Ruth Aranda
LWLaura Waters
Laura Waters
KMKrystal Moya
Krystal Moya
VBVickie Bowcut
Vickie Bowcut
POPeter Olson
Peter Olson
Previous studies implicated protein arginine methyltransferase 5 (PRMT5) as a synthetic lethal target for MTAP-deleted (MTAP del) cancers; however, the pharmacologic characterization of small-molecule inhibitors that recapitulate the synthetic lethal phenotype has not been described. MRTX1719 selectively inhibited PRMT5 in the presence of MTA, which is elevated in MTAP del cancers, and inhibited PRMT5-dependent activity and cell viability with >70-fold selecti­vity in HCT116 MTAP del compared with HCT116 MTAP wild-type (WT) cells. MRTX1719 demonstrated dose-dependent antitumor activity and inhibition of PRMT5-dependent SDMA modification in MTAP del tumors. In contrast, MRTX1719 demonstrated minimal effects on SDMA and viability in MTAP WT tumor xenografts or hematopoietic cells. MRTX1719 demonstrated marked antitumor activity across a panel of xenograft models at well-tolerated doses. Early signs of clinical activity were observed including objective responses in patients with MTAP del melanoma, gallbladder adenocarcinoma, mesothelioma, non–small cell lung cancer, and malignant peripheral nerve sheath tumors from the phase I/II study. Significance: PRMT5 was identified as a synthetic lethal target for MTAP del cancers; however, previous PRMT5 inhibitors do not selectively target this genotype. The differentiated binding mode of MRTX1719 leverages the elevated MTA in MTAP del cancers and represents a promising therapy for the ∼10% of patients with cancer with this biomarker. See related commentary by Mulvaney, p. 2310. This article is featured in Selected Articles from This Issue, p. 2293

1 February 2015 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JRJordi Rodon
Jordi Rodon
MCMichael A. Carducci
Michael A. Carducci
JSJuan M Sepulveda-Sánchez
Juan M Sepulveda-Sánchez
AAAnalia Azaro
Analia Azaro
ECEmiliano Calvo
Emiliano Calvo
JBJose Baselga
Jose Baselga
Purpose: TGFβ signaling plays a key role in tumor progression, including malignant glioma. Small-molecule inhibitors such as LY2157299 monohydrate (LY2157299) block TGFβ signaling and reduce tumor progression in preclinical models. To use LY2157299 in the treatment of malignancies, we investigated its properties in a first-in-human dose (FHD) study in patients with cancer. Experimental Design: Sixty-five patients (58 with glioma) with measurable and progressive malignancies were enrolled. Oral LY2157299 was given as a split dose morning and evening on an intermittent schedule of 14 days on and 14 days off (28-day cycle). LY2157299 monotherapy was studied in dose escalation (part A) first and then evaluated in combination with standard doses of lomustine (part B). Safety was assessed using Common Terminology Criteria for Adverse Events version 3.0, echocardiography/Doppler imaging, serum troponin I, and brain natriuretic peptide (BNP) levels. Antitumor activity was assessed by RECIST and Macdonald criteria. Results: In part A, 16.6% (5/30) and in part B, 7.7% (2/26) of evaluable patients with glioma had either a complete (CR) or a partial response (PR). In both parts, 15 patients with glioma had stable disease (SD), 5 of whom had SD ≥6 cycles of treatment. Therefore, clinical benefit (CR+PR+SD ≥6 cycles) was observed in 12 of 56 patients with glioma (21.4%). LY2157299 was safe, with no cardiac adverse events. Conclusions: On the basis of the safety, pharmacokinetics, and antitumor activity in patients with glioma, the intermittent administration of LY2157299 at 300 mg/day is safe for future clinical investigation. Clin Cancer Res; 21(3); 553–60. ©2014 AACR.

3 May 2021 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
JRJordi Rodon
Jordi Rodon
GAGuillem Argilés
Guillem Argilés
RCRoisin M. Connolly
Roisin M. Connolly
UVUlka Vaishampayan
Ulka Vaishampayan
MJMaja de Jonge
Maja de Jonge
FJFilip Janku
Filip Janku

21 March 2014 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
JRJordi Rodon
Jordi Rodon
IBIrene Brana
Irene Brana
LSLillian L Siu
Lillian L Siu
MJMaja J De Jonge
Maja J De Jonge
NHNatasha Homji
Natasha Homji
JBJohanna C Bendell
Johanna C Bendell

16 September 2024 in Annals of Oncology
Verified
Journal Article
Closed access
JRJ. Rodon
J. Rodon
HPH. Prenen
H. Prenen
ASA. Sacher
A. Sacher
MVM. Villalona-Calero
M. Villalona-Calero
NPN. Penel
N. Penel
BOB.H. O’nEil
B.H. O’nEil